The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI),...
Ausführliche Beschreibung
Autor*in: |
Flora N. Balieva [verfasserIn] Andrew Y. Finlay [verfasserIn] Jörg Kupfer [verfasserIn] Lucía Tomas Aragones [verfasserIn] Lars Lien [verfasserIn] Uwe Gieler [verfasserIn] Françoise Poot [verfasserIn] Gregor B. E. Jemec [verfasserIn] Laurent Misery [verfasserIn] Lajos Kemeny [verfasserIn] Francesca Sampogna [verfasserIn] Henriët van Middendorp [verfasserIn] Jon Anders Halvorsen [verfasserIn] Thomas Ternowitz [verfasserIn] Jacek C. Szepietowski [verfasserIn] Nikolay Potekaev [verfasserIn] Servando E. Marron [verfasserIn] Ilknur K. Altunay [verfasserIn] Sam S. Salek [verfasserIn] Florence J. Dalgard [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2018 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Acta Dermato-Venereologica - Medical Journals Sweden, 2011, 98(2018), 6, Seite 563-569 |
---|---|
Übergeordnetes Werk: |
volume:98 ; year:2018 ; number:6 ; pages:563-569 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.2340/00015555-2918 |
---|
Katalog-ID: |
DOAJ07160118X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ07160118X | ||
003 | DE-627 | ||
005 | 20230309102522.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2340/00015555-2918 |2 doi | |
035 | |a (DE-627)DOAJ07160118X | ||
035 | |a (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RL1-803 | |
100 | 0 | |a Flora N. Balieva |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. | ||
650 | 4 | |a qualityoflife | |
650 | 4 | |a HRQoL | |
650 | 4 | |a DLQI | |
650 | 4 | |a dermatologicaltherapy | |
650 | 4 | |a burdenofskindisease | |
650 | 4 | |a therapyburden | |
653 | 0 | |a Dermatology | |
700 | 0 | |a Andrew Y. Finlay |e verfasserin |4 aut | |
700 | 0 | |a Jörg Kupfer |e verfasserin |4 aut | |
700 | 0 | |a Lucía Tomas Aragones |e verfasserin |4 aut | |
700 | 0 | |a Lars Lien |e verfasserin |4 aut | |
700 | 0 | |a Uwe Gieler |e verfasserin |4 aut | |
700 | 0 | |a Françoise Poot |e verfasserin |4 aut | |
700 | 0 | |a Gregor B. E. Jemec |e verfasserin |4 aut | |
700 | 0 | |a Laurent Misery |e verfasserin |4 aut | |
700 | 0 | |a Lajos Kemeny |e verfasserin |4 aut | |
700 | 0 | |a Francesca Sampogna |e verfasserin |4 aut | |
700 | 0 | |a Henriët van Middendorp |e verfasserin |4 aut | |
700 | 0 | |a Jon Anders Halvorsen |e verfasserin |4 aut | |
700 | 0 | |a Thomas Ternowitz |e verfasserin |4 aut | |
700 | 0 | |a Jacek C. Szepietowski |e verfasserin |4 aut | |
700 | 0 | |a Nikolay Potekaev |e verfasserin |4 aut | |
700 | 0 | |a Servando E. Marron |e verfasserin |4 aut | |
700 | 0 | |a Ilknur K. Altunay |e verfasserin |4 aut | |
700 | 0 | |a Sam S. Salek |e verfasserin |4 aut | |
700 | 0 | |a Florence J. Dalgard |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Acta Dermato-Venereologica |d Medical Journals Sweden, 2011 |g 98(2018), 6, Seite 563-569 |w (DE-627)302725431 |w (DE-600)1492617-9 |x 16512057 |7 nnns |
773 | 1 | 8 | |g volume:98 |g year:2018 |g number:6 |g pages:563-569 |
856 | 4 | 0 | |u https://doi.org/10.2340/00015555-2918 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 |z kostenfrei |
856 | 4 | 0 | |u https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/0001-5555 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1651-2057 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 98 |j 2018 |e 6 |h 563-569 |
author_variant |
f n b fnb a y f ayf j k jk l t a lta l l ll u g ug f p fp g b e j gbej l m lm l k lk f s fs h v m hvm j a h jah t t tt j c s jcs n p np s e m sem i k a ika s s s sss f j d fjd |
---|---|
matchkey_str |
article:16512057:2018----::hrloteaynmarnqaiyfienemtlgclai |
hierarchy_sort_str |
2018 |
callnumber-subject-code |
RL |
publishDate |
2018 |
allfields |
10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569 |
spelling |
10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569 |
allfields_unstemmed |
10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569 |
allfieldsGer |
10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569 |
allfieldsSound |
10.2340/00015555-2918 doi (DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 DE-627 ger DE-627 rakwb eng RL1-803 Flora N. Balieva verfasserin aut The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology Andrew Y. Finlay verfasserin aut Jörg Kupfer verfasserin aut Lucía Tomas Aragones verfasserin aut Lars Lien verfasserin aut Uwe Gieler verfasserin aut Françoise Poot verfasserin aut Gregor B. E. Jemec verfasserin aut Laurent Misery verfasserin aut Lajos Kemeny verfasserin aut Francesca Sampogna verfasserin aut Henriët van Middendorp verfasserin aut Jon Anders Halvorsen verfasserin aut Thomas Ternowitz verfasserin aut Jacek C. Szepietowski verfasserin aut Nikolay Potekaev verfasserin aut Servando E. Marron verfasserin aut Ilknur K. Altunay verfasserin aut Sam S. Salek verfasserin aut Florence J. Dalgard verfasserin aut In Acta Dermato-Venereologica Medical Journals Sweden, 2011 98(2018), 6, Seite 563-569 (DE-627)302725431 (DE-600)1492617-9 16512057 nnns volume:98 year:2018 number:6 pages:563-569 https://doi.org/10.2340/00015555-2918 kostenfrei https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 kostenfrei https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 kostenfrei https://doaj.org/toc/0001-5555 Journal toc kostenfrei https://doaj.org/toc/1651-2057 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 98 2018 6 563-569 |
language |
English |
source |
In Acta Dermato-Venereologica 98(2018), 6, Seite 563-569 volume:98 year:2018 number:6 pages:563-569 |
sourceStr |
In Acta Dermato-Venereologica 98(2018), 6, Seite 563-569 volume:98 year:2018 number:6 pages:563-569 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden Dermatology |
isfreeaccess_bool |
true |
container_title |
Acta Dermato-Venereologica |
authorswithroles_txt_mv |
Flora N. Balieva @@aut@@ Andrew Y. Finlay @@aut@@ Jörg Kupfer @@aut@@ Lucía Tomas Aragones @@aut@@ Lars Lien @@aut@@ Uwe Gieler @@aut@@ Françoise Poot @@aut@@ Gregor B. E. Jemec @@aut@@ Laurent Misery @@aut@@ Lajos Kemeny @@aut@@ Francesca Sampogna @@aut@@ Henriët van Middendorp @@aut@@ Jon Anders Halvorsen @@aut@@ Thomas Ternowitz @@aut@@ Jacek C. Szepietowski @@aut@@ Nikolay Potekaev @@aut@@ Servando E. Marron @@aut@@ Ilknur K. Altunay @@aut@@ Sam S. Salek @@aut@@ Florence J. Dalgard @@aut@@ |
publishDateDaySort_date |
2018-01-01T00:00:00Z |
hierarchy_top_id |
302725431 |
id |
DOAJ07160118X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07160118X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309102522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2340/00015555-2918</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07160118X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Flora N. Balieva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">qualityoflife</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRQoL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DLQI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dermatologicaltherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">burdenofskindisease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapyburden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Y. Finlay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jörg Kupfer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucía Tomas Aragones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Lien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Gieler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Françoise Poot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregor B. E. Jemec</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Misery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lajos Kemeny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sampogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henriët van Middendorp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jon Anders Halvorsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Ternowitz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek C. Szepietowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikolay Potekaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servando E. Marron</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ilknur K. Altunay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sam S. Salek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florence J. Dalgard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Dermato-Venereologica</subfield><subfield code="d">Medical Journals Sweden, 2011</subfield><subfield code="g">98(2018), 6, Seite 563-569</subfield><subfield code="w">(DE-627)302725431</subfield><subfield code="w">(DE-600)1492617-9</subfield><subfield code="x">16512057</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:563-569</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0001-5555</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1651-2057</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="e">6</subfield><subfield code="h">563-569</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Flora N. Balieva |
spellingShingle |
Flora N. Balieva misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
authorStr |
Flora N. Balieva |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)302725431 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RL1-803 |
illustrated |
Not Illustrated |
issn |
16512057 |
topic_title |
RL1-803 The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study qualityoflife HRQoL DLQI dermatologicaltherapy burdenofskindisease therapyburden |
topic |
misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology |
topic_unstemmed |
misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology |
topic_browse |
misc RL1-803 misc qualityoflife misc HRQoL misc DLQI misc dermatologicaltherapy misc burdenofskindisease misc therapyburden misc Dermatology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Acta Dermato-Venereologica |
hierarchy_parent_id |
302725431 |
hierarchy_top_title |
Acta Dermato-Venereologica |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)302725431 (DE-600)1492617-9 |
title |
The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
ctrlnum |
(DE-627)DOAJ07160118X (DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11 |
title_full |
The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
author_sort |
Flora N. Balieva |
journal |
Acta Dermato-Venereologica |
journalStr |
Acta Dermato-Venereologica |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2018 |
contenttype_str_mv |
txt |
container_start_page |
563 |
author_browse |
Flora N. Balieva Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard |
container_volume |
98 |
class |
RL1-803 |
format_se |
Elektronische Aufsätze |
author-letter |
Flora N. Balieva |
doi_str_mv |
10.2340/00015555-2918 |
author2-role |
verfasserin |
title_sort |
role of therapy in impairing quality of life in dermatological patients: a multinational study |
callnumber |
RL1-803 |
title_auth |
The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
abstract |
Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. |
abstractGer |
Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. |
abstract_unstemmed |
Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
6 |
title_short |
The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study |
url |
https://doi.org/10.2340/00015555-2918 https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11 https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918 https://doaj.org/toc/0001-5555 https://doaj.org/toc/1651-2057 |
remote_bool |
true |
author2 |
Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard |
author2Str |
Andrew Y. Finlay Jörg Kupfer Lucía Tomas Aragones Lars Lien Uwe Gieler Françoise Poot Gregor B. E. Jemec Laurent Misery Lajos Kemeny Francesca Sampogna Henriët van Middendorp Jon Anders Halvorsen Thomas Ternowitz Jacek C. Szepietowski Nikolay Potekaev Servando E. Marron Ilknur K. Altunay Sam S. Salek Florence J. Dalgard |
ppnlink |
302725431 |
callnumber-subject |
RL - Dermatology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.2340/00015555-2918 |
callnumber-a |
RL1-803 |
up_date |
2024-07-03T21:10:02.906Z |
_version_ |
1803593714668404736 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07160118X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309102522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2340/00015555-2918</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07160118X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3bfe3b4153a74625b32e859e34803b11</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Flora N. Balieva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">qualityoflife</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HRQoL</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DLQI</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dermatologicaltherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">burdenofskindisease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">therapyburden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrew Y. Finlay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jörg Kupfer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lucía Tomas Aragones</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Lien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Uwe Gieler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Françoise Poot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gregor B. E. Jemec</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Misery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lajos Kemeny</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sampogna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henriët van Middendorp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jon Anders Halvorsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Ternowitz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jacek C. Szepietowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikolay Potekaev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Servando E. Marron</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ilknur K. Altunay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sam S. Salek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florence J. Dalgard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Dermato-Venereologica</subfield><subfield code="d">Medical Journals Sweden, 2011</subfield><subfield code="g">98(2018), 6, Seite 563-569</subfield><subfield code="w">(DE-627)302725431</subfield><subfield code="w">(DE-600)1492617-9</subfield><subfield code="x">16512057</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:98</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:563-569</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3bfe3b4153a74625b32e859e34803b11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2918</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0001-5555</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1651-2057</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">98</subfield><subfield code="j">2018</subfield><subfield code="e">6</subfield><subfield code="h">563-569</subfield></datafield></record></collection>
|
score |
7.399349 |